Blood biomarkers ↔ GBA-targeted therapy

Blood biomarkers GBA-targeted therapy

1 article connects these topics

GT-02287 treatment was linked to an average 81% reduction in blood GluSph levels in patients with elevated baseline levels during a Phase 1b trial.

from With new FDA green light for developer, Parkinson’s clinical trial to launch soon · 2026-07-07

Use of the therapy also reduced levels of glucosylsphingosine (GluSph)... Drops of 81% on average were seen in patients with elevated levels at the beginning of the study.